How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

18,184 results for

"grant funding" or "obtaining grants" or "getting grants" or "grant awards" or (grants and "how to")

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

18101. Multimodality Treatment for Women With Stage II, Stage III, or Stage IV Breast Cancer

Cancer Center ClinicalTrials.gov Identifier: Other Study ID Numbers: LCCC 9818 LCCC9818 ( Other Identifier: UNC Lineberger Comprehensive Cancer Center ) NCI-G00-1836 ( Other Grant/Funding Number: NCI ) First Posted: January 27, 2003 Results First Posted: July 31, 2017 Last Update Posted: July 31, 2017 Last Verified: June 2017 Individual Participant Data (IPD) Sharing Statement: Plan to Share IPD: No Keywords provided by UNC Lineberger Comprehensive Cancer Center: stage II breast cancer stage IV (...) + cyclophosphamide in combination with paclitaxel and trastuzumab (AC-TP) Associated Systolic Dysfunction. Systolic function was measured by the ventricular ejection fraction (LVEF). LVEF is a measurement in determining how well your heart is pumping out blood and in diagnosing and tracking heart failure. Secondary Outcome Measures : Overall Response [ Time Frame: 78 weeks (1.5 years) ] Measured by the Overall Response. Response: Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target

2000 Clinical Trials

18102. Long Term Interferon for Patients Who Did Not Clear Hepatitis C Virus With Standard Treatment

Other Study ID Numbers: HALT C N01-DK-9-2328 ( Other Grant/Funding Number: NIH NIDDK Contract ) N01-DK-9-2323 ( Other Grant/Funding Number: NIH NIDDK Contract ) N01-DK-9-2324 ( Other Grant/Funding Number: NIH NIDDK Contract ) N01-DK-9-2325 ( Other Grant/Funding Number: NIH NIDDK Contract ) N01-DK-9-2326 ( Other Grant/Funding Number: NIH NIDDK Contract ) N01-DK-9-2321 ( Other Grant/Funding Number: NIH NIDDK Contract ) N01-DK-9-2327 ( Other Grant/Funding Number: NIH NIDDK Contract ) N01-DK-9-2319 (...) ( Other Grant/Funding Number: NIH NIDDK Contract ) N01-DK-9-2318 ( Other Grant/Funding Number: NIH NIDDK Contract ) N01-DK-9-2320 ( Other Grant/Funding Number: NIH NIDDK Contract ) N01-DK-9-2322 ( Other Grant/Funding Number: NIH NIDDK Contract ) First Posted: August 9, 2000 Results First Posted: September 4, 2009 Last Update Posted: May 11, 2018 Last Verified: March 2018 Layout table for additional information Studies a U.S. FDA-regulated Drug Product: Yes Studies a U.S. FDA-regulated Device Product

2000 Clinical Trials

18103. Hormone Therapy With Arzoxifene Hydrochloride in Treating Women With Recurrent, Advanced, or Metastatic Endometrial Cancer

First Posted : May 25, 2004 Last Update Posted : June 7, 2012 Sponsor: Eli Lilly and Company Information provided by: Eli Lilly and Company Study Details Study Description Go to Brief Summary: RATIONALE: Estrogen can stimulate the growth of endometrial cancer cells. Hormone therapy using arzoxifene hydrochloride may fight the endometrial cancer by blocking the use of estrogen by the tumor cells PURPOSE: This phase II trial is studying how well arzoxifene hydrochloride works in treating women (...) States, 10021 United States, North Carolina Lineberger Comprehensive Cancer Center, UNC Chapel Hill, North Carolina, United States, 27599-7295 United States, Ohio Arthur G. James Cancer Hospital - Ohio State University Columbus, Ohio, United States, 43210 Grant/Riverside Methodist Hospitals Columbus, Ohio, United States, 43214 United States, Oklahoma University of Oklahoma Health Sciences Center Oklahoma City, Oklahoma, United States, 73190 United States, Pennsylvania Abington Memorial Hospital

1999 Clinical Trials

18104. Vapreotide in Treating Patients Undergoing Elective Pancreatic Resection

: August 10, 2010 Sponsor: Mayo Clinic Collaborator: National Cancer Institute (NCI) Information provided by: Mayo Clinic Study Details Study Description Go to Brief Summary: RATIONALE: Drugs such as vapreotide may prevent complications following pancreatic resection. It is not yet known if vapreotide is more effective than no further therapy in preventing side effects of pancreatic resection. PURPOSE: This randomized phase III trial is studying vapreotide to see how well it works compared to a placebo (...) in Patients Undergoing Elective Pancreatic Resection Grant Application Title: Vapreotide to Prevent Complications of Pancreatic Resection Study Start Date : March 2001 Actual Primary Completion Date : March 2001 Actual Study Completion Date : April 2002 Resource links provided by the National Library of Medicine related topics: resources: Arms and Interventions Go to Outcome Measures Go to Eligibility Criteria Go to Information from the National Library of Medicine Choosing to participate in a study

2001 Clinical Trials

18105. Islet Transplantation for Type 1 Diabetes

. Patients will be given antibiotics to prevent infections. Blood tests to determine how much immunosuppressant drug is in the blood will be performed until the drug is at a stable level. Periodically there will be tests to see if the islet cells are functioning. Blood will be drawn to check drug levels and for other tests routinely. Daily insulin requirements will be checked, and these will be recorded monthly. Patients will be followed for at least 1 year post last islet transplantation. Additional (...) to insulin, thereby showing how much insulin the body is making). Adequate glycemic control is defined by: 1) a blood HbA1c level <6.5%, 2) a blood glucose level after an overnight fast not exceeding 140 mg/dL more than three times in any week and, 3) a 2-hour postprandial blood glucose level not exceeding 180 mg/dL more than four times per week Percent of Participants That Achieved Insulin Independence From First Transplant [ Time Frame: First transplantation until end of study (up to six years post

2001 Clinical Trials

18106. ISIS 2503 in Treating Patients With Advanced Cancer of the Pancreas

More Information Go to Layout table for additonal information Responsible Party: James Posey, MD/ Principal Investigator, University of Alabama at Birmingham ClinicalTrials.gov Identifier: Other Study ID Numbers: CDR0000067701 UAB-9915 ( Other Grant/Funding Number: 0001215 ) ISIS-2503-CS5 UAB-F990526011 NCI-G00-1730 First Posted: May 3, 2004 Last Update Posted: January 4, 2011 Last Verified: December 2010 Keywords provided by University of Alabama at Birmingham: stage III pancreatic cancer

2000 Clinical Trials

18107. Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Ovarian Epithelial Cancer

Center and Research Institute National Cancer Institute (NCI) Investigators Layout table for investigator information Study Chair: Karen K. Fields, MD H. Lee Moffitt Cancer Center and Research Institute More Information Go to Layout table for additonal information Responsible Party: H. Lee Moffitt Cancer Center and Research Institute ClinicalTrials.gov Identifier: Other Study ID Numbers: MCC-12085 MCC-IRB-5418 ( Other Identifier: University of South Florida IRB ) NCI-G00-1745 ( Other Grant/Funding

2000 Clinical Trials

18108. Imatinib Mesylate in Treating Patients With Salivary Gland Cancer

Cancer Centre More Information Go to Publications of Results: Layout table for additonal information Responsible Party: University Health Network, Toronto ClinicalTrials.gov Identifier: Other Study ID Numbers: CDR0000257029 PMH-PHL-009 ( Other Identifier: Princess Margaret Cancer Centre ) NCI-5663 ( Other Grant/Funding Number: NCI ) First Posted: January 27, 2003 Last Update Posted: February 15, 2019 Last Verified: February 2019 Keywords provided by University Health Network, Toronto: recurrent

2002 Clinical Trials

18109. Monoclonal Antibody Therapy in Treating Patients With Lymphoma or Colon Cancer That Has Not Responded to Vaccine Therapy

cells. PURPOSE: This phase II trial is studying anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody to see how well it works in treating patients with lymphoma or colon cancer that has not responded to vaccine therapy. Condition or disease Intervention/treatment Phase Lymphoma Biological: ipilimumab Phase 1 Detailed Description: OBJECTIVES: Primary Determine the toxicity of anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody in patients with follicular or mantle (...) ) Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00047164 Locations Layout table for location information United States, Maryland Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office Bethesda, Maryland, United States, 20892-1182

2002 Clinical Trials

18110. Thalidomide and Irinotecan in Treating Patients With Glioblastoma Multiforme Who Have Undergone Radiation Therapy

( Other Grant/Funding Number: NCI ) First Posted: January 27, 2003 Last Update Posted: October 27, 2011 Last Verified: October 2011 Keywords provided by Dartmouth-Hitchcock Medical Center: adult glioblastoma recurrent adult brain tumor adult giant cell glioblastoma adult gliosarcoma Additional relevant MeSH terms: Layout table for MeSH terms Glioblastoma Nervous System Neoplasms Central Nervous System Neoplasms Astrocytoma Glioma Neoplasms, Neuroepithelial Neuroectodermal Tumors Neoplasms, Germ Cell

2002 Clinical Trials

18111. Hormone Therapy in Preventing Endometrial Cancer in Patients With a Genetic Risk For Hereditary Nonpolyposis Colon Cancer

for investigator information Principal Investigator: Karen Lu M.D. Anderson Cancer Center More Information Go to Layout table for additonal information Responsible Party: National Cancer Institute (NCI) ClinicalTrials.gov Identifier: Other Study ID Numbers: NCI-2013-00466 ID01-340 CDR0000069277 NCI-P02-0218 MDA-ID-01340 N01CN05127 ( Other Grant/Funding Number: US NIH Grant/Contract Award Number ) First Posted: January 27, 2003 Last Update Posted: May 3, 2013 Last Verified: April 2013 Additional relevant MeSH

2002 Clinical Trials

18112. Celecoxib With or Without Eflornithine in Preventing Colorectal Cancer in Patients With Familial Adenomatous Polyposis

recruitment.) First Posted : January 27, 2003 Results First Posted : February 4, 2015 Last Update Posted : February 15, 2017 Sponsor: National Cancer Institute (NCI) Information provided by (Responsible Party): National Cancer Institute (NCI) Study Details Study Description Go to Brief Summary: This randomized phase II trial studies how well giving celecoxib with or without eflornithine works in preventing colorectal cancer in patients with familial adenomatous polyposis. Chemoprevention is the use (...) ) N01-CN-95040 ( Other Identifier: DCP ) N01CN95040 ( Other Identifier: US NIH Grant/Contract Award Number ) First Posted: January 27, 2003 Results First Posted: February 4, 2015 Last Update Posted: February 15, 2017 Last Verified: December 2016 Additional relevant MeSH terms: Layout table for MeSH terms Colorectal Neoplasms Nasopharyngeal Neoplasms Adenomatous Polyposis Coli Intestinal Neoplasms Gastrointestinal Neoplasms Digestive System Neoplasms Neoplasms by Site Neoplasms Digestive System

2002 Clinical Trials

18113. Competing HMOs collaborate to improve preventive services. (PubMed)

Competing HMOs collaborate to improve preventive services. In July 1993, an unusual collaboration developed between competing managed care plans and with competing primary care clinics as part of a federally funded research grant (IMPROVE from the Agency for Health Care Policy and Research). The goal of this collaboration is to scientifically test the ability of an health maintenance organization (HMO) to improve the delivery of eight adult preventive services by training and facilitating (...) the use of continuous quality improvement and prevention systems by contracted private primary clinics.In order to conduct this effectiveness study, it was necessary for two HMOs to come to a structural and functional understanding of how to operate jointly. Investigators recruited 44 private clinics for a randomized controlled trial in which 22 are being assisted in improving the process used to deliver these preventive services and 22 are being left alone as comparison clinics. The intervention

1995 The Joint Commission journal on quality improvement

18114. Factor stationarity and invariance of the POMS in cocaine patients. (PubMed)

scores becomes problematic. Structural equation modeling programs (e.g., LISREL) may be used to explicity test assumptions of factor stationarity and invariance. As part of a National Institute on Drug Abuse grant-funded, double-blind, placebo-controlled trial to assess effectiveness of treating cocaine-abusing patients with fluoxetine, POMS data were collected at baseline and at 6 weeks (n = 90). Applying a longitudinal factor analysis strategy, factor stationarity and invariance of two POMS factors

1993 Psychopharmacology bulletin

18115. Effects of welfare reform on teenage parents and their children. (PubMed)

, child care assistance, and education and training opportunities. This article reviews the policy context in which the Teenage Parent Welfare Demonstration was designed and implemented, and describes how participation in the enhanced services group affected the teen mothers as adults and as parents. Results showed that, for the reasonable aggregate annual cost of $2,400 per participant, the program increased the 'teenagers' attendance at school and job training programs, and modestly increased (...) the proportion who were employed to 48%, compared with 43% among those receiving regular welfare services. As the participants' earnings from employment increased, their welfare grants shrank. Because these changes offset each other, the program did not improve the economic well-being of the families, although fewer tax dollars were needed to support them. The program did not discourage further childbearing, however, or affect either the parenting behavior of the young women or the development

1996 The Future of children / Center for the Future of Children, the David and Lucile Packard Foundation

18116. Management of Patent Ductus in Premature Infants

: Other Study ID Numbers: 13 R01HL023121 ( Other Grant/Funding Number: US NIH Grant Number ) First Posted: October 28, 1999 Last Update Posted: December 13, 2013 Last Verified: April 2012 Additional relevant MeSH terms: Layout table for MeSH terms Cardiovascular Diseases Heart Diseases Ductus Arteriosus, Patent Congenital Abnormalities Heart Defects, Congenital Cardiovascular Abnormalities Indomethacin Anti-Inflammatory Agents, Non-Steroidal Analgesics, Non-Narcotic Analgesics Sensory System Agents

1999 Clinical Trials

18117. Coronary Drug Project Mortality Surveillance

ClinicalTrials.gov Identifier: Other Study ID Numbers: 2 R01HL008888-14S1 ( Other Grant/Funding Number: US NIH Grant Number ) First Posted: October 28, 1999 Last Update Posted: November 26, 2013 Last Verified: April 2004 Additional relevant MeSH terms: Layout table for MeSH terms Infarction Cardiovascular Diseases Heart Diseases Myocardial Infarction Ischemia Coronary Disease Coronary Artery Disease Myocardial Ischemia Pathologic Processes Necrosis Vascular Diseases Arteriosclerosis Arterial Occlusive Diseases

1999 Clinical Trials

18118. Coronary Drug Project

. JAMA, 234:22-23, l975. Coronary Drug Project Research Group: The Coronary Drug Project: Implications for Clinical Care. Primary Care, 4:247-253, l977. Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number): Layout table for additonal information ClinicalTrials.gov Identifier: Other Study ID Numbers: 1 R01HL008888-14 ( Other Grant/Funding Number: US NIH Grant Number ) First Posted: October 28, 1999 Last Update Posted: November 26, 2013 Last Verified: July 2004 (...) recommendation for implementation; the study was begun in 1965. Supported by the grant mechanism, the trial involved 53 participating clinics, a coordinating center, central laboratory, ECG center, drug procurement and distribution center, and NHI medical liaison office, and a policy board, steering committee, and 12 other committees (e.g., a data and safety monitoring committee). The first patient was randomly allocated to treatment in March 1966 and the last in October 1969. Each patient reported

1999 Clinical Trials

18119. Mechanisms of Inflammatory Liver Injury

to Brief Summary: White blood cells can cause liver damage if they inappropriately accumulate in the liver in large numbers. Such an event can occur if an individual's blood is exposed to endotoxin, a substance released from the cell walls of many species of bacteria. The purpose of this study is to isolate neutrophils, an important white blood cell, from the blood of normal volunteers, and put them in tissue culture with isolated liver cells. The experiments will determine how endotoxin can increase (...) the ability of neutrophils to damage liver cells. All studies supported by this grant will be done with isolated cells in tissue culture. This experimental model will reveal possible mechanisms that can in the future be evaluated in human diseases such as bacterial sepsis. Condition or disease Liver Diseases Detailed Description: Neutrophils will be isolated from normal human volunteers and placed in cell culture with isolated hepatocytes or C3A cells (hepatoblastoma cell line that exhibit many

2001 Clinical Trials

18120. Allogeneic Mixed Chimerism Stem Cell Transplant Using Campath for Hemoglobinopathies & Bone Marrow Failure Syndromes

-G99-1617 ( Other Grant/Funding Number: National Cancer Institute ) CDR0000067374 First Posted: January 27, 2003 Results First Posted: November 11, 2013 Last Update Posted: December 5, 2014 Last Verified: November 2014 Keywords provided by David Rizzieri, MD, Duke University: sickle cell anemia severe aplastic anemia Additional relevant MeSH terms: Layout table for MeSH terms Anemia Anemia, Aplastic Anemia, Sickle Cell Hemoglobinuria Hemoglobinuria, Paroxysmal Hemoglobinopathies Pancytopenia Red

1999 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>